Current Problems in Cardiology最新文献

{"title":"Value of extreme left axis deviation in patients with complete left bundle branch block","authors":"Guido Vannoni MD,&nbsp;Carlos D. Labadet MD,&nbsp;Giuliana Caminotti MD,&nbsp;Bárbara Zambudio MD,&nbsp;Juan M. Fiamengo Tch,&nbsp;Lucas N. Campana MD,&nbsp;María V. Vannoni MD,&nbsp;Gerardo M. Marambio MD,&nbsp;Jorge A. Lax MD,&nbsp;Juan A. Gagliardi MD, PhD","doi":"10.1016/j.cpcardiol.2025.103174","DOIUrl":"10.1016/j.cpcardiol.2025.103174","url":null,"abstract":"<div><h3>Introduction</h3><div>Complete left bundle branch block (LBBB) is associated with increased risk of cardiovascular events. The value of extreme deviation of the QRS axis to the left (LAD) in the context of LBBB is controversial.</div></div><div><h3>Objective</h3><div>To evaluate whether LAD (-45°) in patients with LBBB is a marker of systolic dysfunction and ventricular remodeling.</div></div><div><h3>Material and methods</h3><div>Cross-sectional cohort study including 102 patients with LBBB who underwent echocardiography to assess left ventricular (LV) diameters, wall thickness and ejection fraction (EF).</div></div><div><h3>Results</h3><div>Mean age was 67.9 ± 13 years. 48 % were women. 80.4 % met Strauss criteria for LBBB and 28.4 % had LAD. The LAD group showed lower EF (32.2 ± 12 % vs. 46.7 ± 17 %, p = 0.00009) and higher LV end-diastolic diameter index (34.8 ± 9 vs. 30.9 ± 6, p = 0.011). LAD had 45 % sensitivity, 88 % specificity, positive predictive value of 0.79 and negative predictive value of 0.62 for identifying reduced EF. Cardiomyopathy diagnosis was more frequent in the LAD group (93.1 % vs. 61.6 %; p = 0.0016). LV hypertrophy prevalence was similar between groups, but LAD patients had higher prevalence of eccentric LV hypertrophy.</div></div><div><h3>Conclusion</h3><div>In LBBB, LAD (-45°) identifies patients with worse systolic function, greater degree of LV dilatation, and more eccentric hypertrophy. Additionally, cardiomyopathy prevalence was higher in this population.</div></div>","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 11","pages":"Article 103174"},"PeriodicalIF":3.3,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145056169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex differences in in-hospital outcomes in hypertrophic cardiomyopathy: A nationwide analysis","authors":"Ahmed M. Saad MD ,&nbsp;Mohammed Abozenah MD ,&nbsp;Colby Salerno DO ,&nbsp;Andrew M. Goldsweig MD, MS","doi":"10.1016/j.cpcardiol.2025.103172","DOIUrl":"10.1016/j.cpcardiol.2025.103172","url":null,"abstract":"<div><h3>Background</h3><div>Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy. HCM is associated with heart failure (HF), arrhythmia, and acute coronary syndrome (ACS). The influence of sex on in-hospital outcomes in HCM is unknown. We conducted a nationwide analysis to compare outcomes between women and men with HCM hospitalized for HF, arrhythmias, or ACS.</div></div><div><h3>Methods</h3><div>This retrospective cohort analysis of the 2022 National Inpatient Sample (NIS) identified adults hospitalized with acute HF, arrhythmia, or ACS plus a secondary diagnosis of HCM. The primary outcome was in-hospital mortality. Secondary outcomes included length of stay (LOS) and total hospital charges. Multivariable logistic and linear regression models were used to adjust for demographics and comorbidities.</div></div><div><h3>Results</h3><div>Among 5,089 HCM admissions (51.1 % female; mean age 65.9 years), women were older (68.9 vs. 62.1 years) and more often admitted for acute HF. Arrhythmia presentations were similarly common in both sexes, and men more frequently had ACS. In-hospital mortality was 1.7 % and did not differ by sex after adjustment (adjusted odds ratio 1.3, <em>p</em> = 0.63). Mean LOS was 4.3 days and was similar between sexes. Total hospitalization charges showed no significant sex difference for HF or ACS, but men incurred higher charges for arrhythmias.</div></div><div><h3>Conclusions</h3><div>In this nationwide analysis, sex was not an independent predictor of in-hospital mortality or LOS among admissions with HCM and acute cardiovascular events. Resource utilization was broadly comparable except for arrhythmia admissions, where charges were substantially higher in men. Differences in hospital charges suggest that differences in management may exist.</div></div>","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 11","pages":"Article 103172"},"PeriodicalIF":3.3,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145056236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Knowledge mapping of SGLT2-inhibitors and cardiovascular outcomes: A bibliometric analysis","authors":"Aysa Rezabakhsh ,&nbsp;Hadis Iraji ,&nbsp;Ashot Avagimyan ,&nbsp;Elena Aghajanova ,&nbsp;Zinaida Jndoyan ,&nbsp;Lilia Mirzoyan ,&nbsp;Waseem Hassan ,&nbsp;Solomon Habtemariam ,&nbsp;Anne Meddahi-Pellé ,&nbsp;Graciela Pavon-Djavid ,&nbsp;Abolfazl Barzegri","doi":"10.1016/j.cpcardiol.2025.103171","DOIUrl":"10.1016/j.cpcardiol.2025.103171","url":null,"abstract":"<div><h3>Introduction</h3><div>Initially developed for the treatment of type 2 diabetes mellitus (T2DM), SGLT2 inhibitors have increasingly been recognized for their substantial cardiovascular, renal, and metabolic benefits. This study undertakes a systematic bibliometric analysis to delineate research trends, quantify advancements, and identify influential studies on SGLT2 inhibitors and cardiovascular outcomes.</div></div><div><h3>Methods</h3><div>A comprehensive literature search was performed using the Scopus database, resulting in 10,211 documents up to the search date. Both original research articles and reviews (narrative and systematic) were included. Quantitative metrics such as publication count, citation analysis, and authorship were employed. Network visualization tools (e.g., VOSviewer) and bibliometric software (R Studio with bibliometrix packages) were used to analyze collaboration networks, keyword co-occurrence, and thematic clustering.</div></div><div><h3>Results</h3><div>The analysis revealed a significant upward trend in publication volume, with a notable peak in recent years, indicating a heightened interest in the topic among scientists. The United States and selected European institutions emerged as major contributors, with prominent authors and funding sources influencing the research output. Thematic analysis highlighted a focus on cardiovascular diseases, heart failure, renal outcomes, and mechanistic studies of SGLT2 inhibitor action. Notably, landmark randomized controlled trials have reported significant reductions in cardiovascular mortality, heart failure hospitalizations, and progression of kidney disease.</div></div><div><h3>Conclusion</h3><div>This study underscores the transformative impact of SGLT2 inhibitors on cardiovascular therapy. The analytical framework highlights the expansion of the field, and the integration of translational research.</div></div>","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 12","pages":"Article 103171"},"PeriodicalIF":3.3,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145056183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The triadic relationship between nonalcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease: From molecular mechanisms to clinical management","authors":"Yuxi Jin ,&nbsp;Mohammed Alissa ,&nbsp;Ahmed Ezzat Ahmed ,&nbsp;Amin A. Al-Doaiss ,&nbsp;Naif Asiri ,&nbsp;Yasser Assiri ,&nbsp;Shahid Ullah Khan Phd ,&nbsp;Munir Ullah Khan ,&nbsp;Samuel Joseph","doi":"10.1016/j.cpcardiol.2025.103170","DOIUrl":"10.1016/j.cpcardiol.2025.103170","url":null,"abstract":"<div><div>Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) represent interconnected metabolic disorders with multifaceted etiology, demonstrating bidirectional relationships and pronounced associations with cardiovascular diseases (CVDs). Despite extensive research, significant knowledge gaps persist regarding the temporal progression of these comorbidities, optimal screening strategies for high-risk populations, and personalized therapeutic approaches targeting the hepatic-cardiac-metabolic axis simultaneously. Current literature lacks a comprehensive analysis of phenotypic heterogeneity within NAFLD-T2DM-CVD clusters and fails to address sex-specific and ethnic variations in disease progression patterns adequately. A systematic literature search was conducted across PubMed, Medline, Embase, Web of Science, and Google Scholar databases from inception to June 2024, employing various combinations of terms including NAFLD, NASH, T2DM, and CVDs, with emphasis on identifying mechanistic pathways, epidemiological trends, and therapeutic innovations. This review identifies novel pathophysiological mechanisms linking hepatic steatosis, insulin resistance, and cardiovascular dysfunction, including previously underexplored roles of gut microbiome dysbiosis, advanced glycation end products, and epigenetic modifications. Emerging evidence suggests distinct molecular signatures that could facilitate precision medicine approaches. The intricate interplay between diabetes, hepatic dysfunction, and cardiovascular complications represents a global health challenge requiring integrated management strategies. Future research should prioritize developing biomarker-guided therapeutic algorithms, investigating sex-specific treatment responses, and establishing standardized protocols for concurrent NAFLD-T2DM-CVD management to optimize clinical outcomes and reduce healthcare burden.</div></div>","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 11","pages":"Article 103170"},"PeriodicalIF":3.3,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145006870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HER2-targeted therapies and cardiotoxicity: From major concern to manageable risk","authors":"Rio Putra Pamungkas MD ,&nbsp;Laras Pratiwi MD ,&nbsp;Henry Sutanto MD, MSc, PhD","doi":"10.1016/j.cpcardiol.2025.103168","DOIUrl":"10.1016/j.cpcardiol.2025.103168","url":null,"abstract":"<div><div>HER2-targeted therapies have dramatically improved outcomes for patients with HER2-positive breast cancer, but their potential for cardiotoxicity remains a critical clinical concern. Early trials reported high rates of cardiac dysfunction, particularly with concomitant anthracycline use, prompting the development of intensive cardiac monitoring strategies. However, emerging evidence suggests that most cardiotoxic events are asymptomatic, reversible, and rarely require permanent treatment discontinuation, particularly with newer agents such as antibody–drug conjugates. Clinical determinants include baseline left ventricular dysfunction, age, comorbidities, and combination chemotherapy, while biomarkers and advanced imaging are promising tools for early detection. Mechanistically, HER2 inhibition disrupts cardiomyocyte survival pathways and mitochondrial function, but the relationship between these changes and clinically meaningful heart failure remains incompletely defined. Recent studies, including SAFE-HEaRt, demonstrate that HER2 therapy can often be safely continued under cardio-oncology supervision with appropriate cardioprotective interventions. Nevertheless, gaps persist in risk stratification, long-term surveillance, and the integration of biomarkers and imaging into routine practice. This article critically examines the pathophysiology, clinical risk factors, and management of HER2 therapy-induced cardiotoxicity, ultimately arguing that with proper monitoring and multidisciplinary care, cardiotoxicity should not preclude optimal oncologic treatment.</div></div>","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 11","pages":"Article 103168"},"PeriodicalIF":3.3,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145006889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of 0.5 mg dose of colchicine on clinical outcomes in patients with acute myocardial infarction: An updated meta-analysis of randomized controlled trials","authors":"Ahmed Nazmy MD ,&nbsp;Ahmed Sobhy MD ,&nbsp;Ahmed Elshahat MD ,&nbsp;Karim Atta MD ,&nbsp;Mohamed R. Murad MD ,&nbsp;Moustafa Ibrahim MD ,&nbsp;Hassan El-Shirbiny MD ,&nbsp;Rahma Abdelfattah Ibrahim MD ,&nbsp;Mohamed Saad Sayed MD ,&nbsp;Mahmoud Gomaa MD ,&nbsp;Ahmed Yasser Shaban MD ,&nbsp;Mohamed Naeem MD ,&nbsp;Ahmed Abdelaziz MD","doi":"10.1016/j.cpcardiol.2025.103169","DOIUrl":"10.1016/j.cpcardiol.2025.103169","url":null,"abstract":"<div><h3>Background</h3><div>Inflammation plays a critical role in the progression of atherosclerosis, and the anti-inflammatory effects on clinical outcomes of patients with acute myocardial infarction (AMI) are still uncertain.</div></div><div><h3>Objectives</h3><div>We aimed to study the effects of a 0.5 mg dose of colchicine on clinical outcomes following AMI.</div></div><div><h3>Methods</h3><div>We systematically searched PubMed, Scopus, Web of Science, and Cochrane Central from inception to January 2025 for randomized controlled trials (RCTs) assessing 0.5 mg colchicine in AMI patients. The primary outcome was the incidence of major adverse cardiovascular events (MACE). Secondary outcomes included individual MACE components, cardiovascular (CV) and non-CV mortality, atrial fibrillation (AF), hospital readmission, and gastrointestinal (GIT) adverse events, including diarrhea.</div></div><div><h3>Results</h3><div>Ten RCTs involving 13,623 patients with a median follow-up of 6 months (range 5 days–36 months) were included. Low-dose colchicine showed a non-significant trend toward reducing MACE versus placebo (RR = 0.90, 95% CI: 0.80–1.01, p = 0.07; I² = 0%). Hospital readmission was significantly reduced by 49% (OR = 0.51, 95% CI: 0.26–0.98, p = 0.04; number needed to treat [NNT] = 25). Colchicine increased the risk of diarrhea (RR = 1.58, 95% CI: 1.06–2.36, p = 0.03; I² = 71%; number needed to harm [NNH] = 50) but showed no significant differences in all-cause mortality, CV mortality, myocardial infarction, stroke, or other GIT events.</div></div><div><h3>Conclusion</h3><div>Low-dose colchicine had a lower hospital readmission rate, but with higher rates of diarrhea compared to placebo. Long-term assessment is indeed to validate the current findings.</div></div>","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 11","pages":"Article 103169"},"PeriodicalIF":3.3,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145006813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editor’s Message","authors":"","doi":"10.1016/S0146-2806(25)00179-3","DOIUrl":"10.1016/S0146-2806(25)00179-3","url":null,"abstract":"","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 10","pages":"Article 103159"},"PeriodicalIF":3.3,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144931861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guidelines for Authors","authors":"","doi":"10.1016/S0146-2806(25)00182-3","DOIUrl":"10.1016/S0146-2806(25)00182-3","url":null,"abstract":"","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 10","pages":"Article 103162"},"PeriodicalIF":3.3,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144931862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Information for Readers","authors":"","doi":"10.1016/S0146-2806(25)00181-1","DOIUrl":"10.1016/S0146-2806(25)00181-1","url":null,"abstract":"","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 10","pages":"Article 103161"},"PeriodicalIF":3.3,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144931864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Title Page","authors":"","doi":"10.1016/S0146-2806(25)00178-1","DOIUrl":"10.1016/S0146-2806(25)00178-1","url":null,"abstract":"","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 10","pages":"Article 103158"},"PeriodicalIF":3.3,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144931860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}